A first-in-human clinical trial tests a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers.

Researchers have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers. The results show ...

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions—but there is always room ...

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing ...

Adoptive cell therapy based on ex-vivo expanded tumor-infiltrating lymphocytes (TILs) has historically been most effective in ...

Plant breeding plays a vital role in ensuring global food security by increasing crop yields, improving nutritional quality ...

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) ...

Researchers have developed a machine learning model that predicts Cas9 proteins that can be tailored with designer properties for therapeutic use.

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

The CRISPR Market had an estimated market share worth USD 3.4 billion in 2023, and it is predicted to reach a global market valuation of USD 17.8 billion by 2034, growing at a CAGR of 16.1% from 2024 ...

Casgevy (exagamglogene autotemcel or exa-cel) became the first drug based on the CRISPR/Cas9 gene-editing technology to be approved towards the end of last year, when it was cleared by the FDA for ...